Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients

NCT00603902 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00603902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00603902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2008
Completion date
August 31, 2009
Enrollment
4,008 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity